INTERVENTIONAL GLAUCOMA: SLT AND MIGS
A Roundtable Discussion Of Nondestructive Interventional Treatments For Open-angle Glaucoma
Cataract & Refractive Surgery Today
SUPPLEMENT | AUGUST 2018
Sponsored by Ellex Medical
Source: https://crstoday.com/articles/2018-aug/interventional-glaucoma-slt-and-migs/
-----
Iqbal Ike K. Ahmed, MD, FRCSC, introduces this roundtable discussion of different paradigms in glaucoma therapy, with Mahmoud A. Khaimi, MD; Mark J. Gallardo, MD; David Richardson, MD; Nathan M. Radcliffe, MD; and I. Paul Singh, MD. The surgeons share their current treatment strategies for open-angle glaucoma and discuss how to incorporate selective laser trabeculoplasty and minimally invasive glaucoma surgery (MIGS) into practice.
-----
At ASCRS 2018 in Washington, DC, a group of surgeons experienced in interventional glaucoma therapies sat down to discuss the roles of selective laser trabeculoplasty (SLT) and microinvasive glaucoma surgery (MIGS) for treatment of openangle glaucoma (OAG).
The term interventional glaucoma refers to more than simply technology. It is a mindset that the available technologies bring to us as surgeons and clinicians. Instead of being passive and watchful, waiting for our patients to progress, interventional glaucoma allows us to be actively involved in their care by providing interventional therapies that change the course of the disease. I am very excited about interventional glaucoma and how it shapes the future of glaucoma care.
In this roundtable, we will discuss a number of technologies used in the interventional glaucoma model. First, we want to hear about SLT and its relevance in glaucoma therapy today, including the interplay of SLT and MIGS options. We also will talk about our experiences with ab interno canaloplasty (ABiC) performed with the iTrack surgical system (Ellex), its role in rejuvenating the natural outflow system, and its place among MIGS procedures.
—Iqbal “Ike” K. Ahmed, MD, FRCSC, Moderator
This document summarizes a journal club presentation on a study investigating the safety and efficacy of lower doses (0.01%, 0.1%, and 0.5%) of atropine for treating childhood myopia. The study involved 400 children aged 6-12 years with myopia who were randomized to receive one of the three atropine doses nightly for 2 years. Results showed a dose-dependent response, with the 0.5% dose slowing myopia progression the most but also causing more side effects like diminished accommodation and larger pupils. The 0.01% dose had the smallest effect on slowing progression but caused minimal side effects. Overall, lower doses of atropine showed potential as an alternative treatment with fewer visual side
This document summarizes minimally invasive glaucoma surgery (MIGS) procedures. MIGS offers more modest intraocular pressure (IOP) lowering than traditional glaucoma surgery, but with a safer risk profile. The document describes various MIGS procedures including the iStent, Hydrus, CyPass, and XEN gel stent. It provides details on the mechanism of action, surgical technique, efficacy and safety data from clinical studies for each procedure. MIGS provides an alternative treatment option for glaucoma patients to lower IOP and reliance on eye drops without the risks of more invasive surgeries.
Newer modalities in diagnosis of glaucomaBipin Bista
Digital imaging technologies like confocal scanning laser ophthalmoscopy (CSLO), scanning laser polarimetry (SLP), and optical coherence tomography (OCT) provide objective and reproducible measurements of the optic nerve head and retinal nerve fiber layer thickness to detect and monitor glaucoma. These modalities have improved over the past decade with enhancements like enhanced corneal compensation and spectral domain OCT. Detection of glaucomatous damage relies on progressive changes in neuroretinal rim area, cupping of the optic disc, retinal nerve fiber layer thinning, and trend-based or event-based analyses of measurements over time. While SLP may detect nerve fiber layer damage earlier than OCT, detection of damage requires analysis of changes in measurements rather
This document provides an evaluation of proptosis (abnormal protrusion of the eyeball) through a detailed algorithm and assessment process. It begins by defining key terms like exophthalmos and differentiating causes of proptosis. The evaluation involves a thorough history, eye examination measuring proptosis, assessing any mass, and appropriate imaging and tests. Causes of proptosis are classified as infectious, inflammatory, vascular, traumatic, pseudoproptosis, or neoplastic. Key imaging modalities like CT are discussed. Common etiologies like Graves' disease, infections, and tumors are highlighted.
Optical Coherence Tomography - principle and uses in ophthalmologytapan_jakkal
Optical coherence tomography (OCT) is a non-invasive imaging technique that uses light to capture high-resolution, cross-sectional images of the retina and anterior segment of the eye. OCT provides depth resolution on the scale of 10 microns, allowing it to visualize detailed layers and structures within the retina. OCT can be used to qualitatively and quantitatively analyze the retina, detecting various pathological features and measuring retinal thickness. Anterior segment OCT also allows high-resolution imaging of the cornea, iris, angle, and anterior chamber.
This document discusses perimetry and visual field testing. It defines visual field as the area that can be seen at a given moment. There are various methods of visual field testing including kinetic and static perimetry. Automated static perimetry tests like Humphrey and Octopus are now commonly used and test the threshold light intensity that can be detected at different points in the visual field. The results are analyzed based on total deviation plots, pattern deviation plots and global indices to detect and monitor glaucomatous visual field defects. Common patterns of visual field defects seen in different conditions are also described.
This document presents a case study of intermittent exotropia in a 3-year-old female patient. On examination, the patient was found to have an alternating exotropia when measuring the angle of deviation at distance and near. She was diagnosed with intermittent exotropia. For treatment, the patient underwent 6 weeks of patching therapy and showed orthotropia on follow up visits. She later underwent bilateral lateral rectus recession surgery, with good control of exotropia observed at subsequent reviews. The document also provides background information on intermittent exotropia including prevalence, etiology, symptoms, classification, evaluation, treatment options, and surgical outcomes.
Prism is a portion of a refractive medium with two plane surfaces inclined at an angle. It causes light to deviate due to refraction. Prisms are used in ophthalmology to diagnose and manage eye alignment issues like strabismus. Key diagnostic uses include measuring the angle of deviation using prism alternate cover test and investigating binocular single vision through tests like the prism reflex test and prism vergence testing. Prisms are also used therapeutically to correct angles of deviation in conditions like esotropia and exotropia.
This document summarizes a journal club presentation on a study investigating the safety and efficacy of lower doses (0.01%, 0.1%, and 0.5%) of atropine for treating childhood myopia. The study involved 400 children aged 6-12 years with myopia who were randomized to receive one of the three atropine doses nightly for 2 years. Results showed a dose-dependent response, with the 0.5% dose slowing myopia progression the most but also causing more side effects like diminished accommodation and larger pupils. The 0.01% dose had the smallest effect on slowing progression but caused minimal side effects. Overall, lower doses of atropine showed potential as an alternative treatment with fewer visual side
This document summarizes minimally invasive glaucoma surgery (MIGS) procedures. MIGS offers more modest intraocular pressure (IOP) lowering than traditional glaucoma surgery, but with a safer risk profile. The document describes various MIGS procedures including the iStent, Hydrus, CyPass, and XEN gel stent. It provides details on the mechanism of action, surgical technique, efficacy and safety data from clinical studies for each procedure. MIGS provides an alternative treatment option for glaucoma patients to lower IOP and reliance on eye drops without the risks of more invasive surgeries.
Newer modalities in diagnosis of glaucomaBipin Bista
Digital imaging technologies like confocal scanning laser ophthalmoscopy (CSLO), scanning laser polarimetry (SLP), and optical coherence tomography (OCT) provide objective and reproducible measurements of the optic nerve head and retinal nerve fiber layer thickness to detect and monitor glaucoma. These modalities have improved over the past decade with enhancements like enhanced corneal compensation and spectral domain OCT. Detection of glaucomatous damage relies on progressive changes in neuroretinal rim area, cupping of the optic disc, retinal nerve fiber layer thinning, and trend-based or event-based analyses of measurements over time. While SLP may detect nerve fiber layer damage earlier than OCT, detection of damage requires analysis of changes in measurements rather
This document provides an evaluation of proptosis (abnormal protrusion of the eyeball) through a detailed algorithm and assessment process. It begins by defining key terms like exophthalmos and differentiating causes of proptosis. The evaluation involves a thorough history, eye examination measuring proptosis, assessing any mass, and appropriate imaging and tests. Causes of proptosis are classified as infectious, inflammatory, vascular, traumatic, pseudoproptosis, or neoplastic. Key imaging modalities like CT are discussed. Common etiologies like Graves' disease, infections, and tumors are highlighted.
Optical Coherence Tomography - principle and uses in ophthalmologytapan_jakkal
Optical coherence tomography (OCT) is a non-invasive imaging technique that uses light to capture high-resolution, cross-sectional images of the retina and anterior segment of the eye. OCT provides depth resolution on the scale of 10 microns, allowing it to visualize detailed layers and structures within the retina. OCT can be used to qualitatively and quantitatively analyze the retina, detecting various pathological features and measuring retinal thickness. Anterior segment OCT also allows high-resolution imaging of the cornea, iris, angle, and anterior chamber.
This document discusses perimetry and visual field testing. It defines visual field as the area that can be seen at a given moment. There are various methods of visual field testing including kinetic and static perimetry. Automated static perimetry tests like Humphrey and Octopus are now commonly used and test the threshold light intensity that can be detected at different points in the visual field. The results are analyzed based on total deviation plots, pattern deviation plots and global indices to detect and monitor glaucomatous visual field defects. Common patterns of visual field defects seen in different conditions are also described.
This document presents a case study of intermittent exotropia in a 3-year-old female patient. On examination, the patient was found to have an alternating exotropia when measuring the angle of deviation at distance and near. She was diagnosed with intermittent exotropia. For treatment, the patient underwent 6 weeks of patching therapy and showed orthotropia on follow up visits. She later underwent bilateral lateral rectus recession surgery, with good control of exotropia observed at subsequent reviews. The document also provides background information on intermittent exotropia including prevalence, etiology, symptoms, classification, evaluation, treatment options, and surgical outcomes.
Prism is a portion of a refractive medium with two plane surfaces inclined at an angle. It causes light to deviate due to refraction. Prisms are used in ophthalmology to diagnose and manage eye alignment issues like strabismus. Key diagnostic uses include measuring the angle of deviation using prism alternate cover test and investigating binocular single vision through tests like the prism reflex test and prism vergence testing. Prisms are also used therapeutically to correct angles of deviation in conditions like esotropia and exotropia.
This document discusses target intraocular pressure (IOP) for treating glaucoma. It defines target IOP as the upper limit of IOP that prevents further glaucoma damage. Establishing an individualized target IOP is important to slow retinal ganglion cell loss and glaucoma progression over a patient's lifetime with minimal effects on quality of life. The target IOP should be based on factors like the amount of existing eye damage, maximum past IOP levels, life expectancy, and risk factors. The target is dynamic and must be reevaluated periodically, lowering it if damage progresses or raising it if side effects occur from low IOP. Clinical studies show that greater IOP reductions correlate with less glaucoma progression
Circumscribed choroidal hemangioma is a benign vascular tumor that occurs as an orange-red mass in the posterior pole of the eye. It most commonly causes decreased vision through serous retinal detachment. Diagnosis can be challenging as it is often initially misdiagnosed as choroidal melanoma or metastasis. Imaging such as ultrasound, fluorescein angiography, and MRI help differentiate it from other lesions. Asymptomatic lesions may be observed, while visually threatening lesions require treatment such as photodynamic therapy, laser photocoagulation, or radiotherapy. Factors like delayed treatment and poor initial vision predict a worse visual outcome.
Traumatic cataracts are caused by blunt or penetrating ocular trauma and can form immediately or years later. The majority require surgery. Factors like mechanism of injury, lens morphology, integrity of structures like the capsule and zonules, and presence of other ocular injuries must be considered for surgical planning. Cataract extraction techniques may include phacoemulsification, extracapsular extraction, or lensectomy depending on the case. Postoperative care involves managing complications and determining appropriate intraocular lens placement. Prognosis depends on initial findings and injuries per the Ocular Trauma Score.
Optical coherence tomography (OCT) is useful for imaging both the anterior and posterior segments in glaucoma. Posterior segment OCT allows quantification of retinal nerve fiber layer thickness, optic nerve head parameters, and ganglion cell layer thickness. Changes in these measurements over time can help detect glaucomatous progression. Anterior segment OCT visualizes angle anatomy and structures after glaucoma surgery. OCT provides objective data but results must be interpreted carefully while considering limitations such as variability between devices and lack of representation in normative databases.
Optic atrophy refers to changes in the optic nerve resulting from axonal degeneration between the retina and lateral geniculate body, causing visual disturbance and changes in the optic nerve head appearance. It can be classified as primary, secondary, or consecutive. Primary optic atrophy occurs without prior nerve swelling and may result from lesions along the visual pathway. Secondary optic atrophy is preceded by long-term nerve swelling and includes causes like chronic papilledema. Consecutive optic atrophy is caused by diseases of the inner retina or its blood supply. Neuroretinitis refers to optic neuritis with retinal inflammation, most commonly caused by cat scratch fever, and presents with papillitis, macular edema, and sometimes a macular
This document discusses minimally invasive glaucoma surgery (MIGS) procedures. It defines MIGS as glaucoma surgery that is ab interno, uses a small incision, spares the conjunctiva, causes minimal trauma and tissue disruption, has a high safety profile, allows for rapid visual recovery, and can be combined with cataract surgery. It then describes various MIGS procedures including trabecular micro-bypass stents, gonioscopy assisted transluminal trabeculotomy, excimer laser trabeculotomy, the iStent, and suprachoroidal shunts. It provides details on the mechanisms, surgical techniques, indications, and complications of these different MIGS procedures.
1. The document presents a case of a 20-year-old male with involuntary eye movements since birth, blurry distant vision for 5 years, and recurrent eye pain and discomfort for 7 years. Examination found nystagmus and a diagnosis of infantile nystagmus syndrome was made.
2. The discussion section defines nystagmus and its mechanisms, describes features like waveforms and territories, and covers types of nystagmus including congenital sensory deficit nystagmus, congenital motor nystagmus, and spasmus nutans.
3. Congenital nystagmus is often idiopathic but can be hereditary, and genetic factors like mutations
Myopic Maculopathy refers to pathologies that can occur in the macula as a result of high myopia and pathological myopia. Some key pathologies discussed in the document include posterior staphyloma, lacquer cracks, macular hemorrhage, myopic foveoschisis, myopic macular hole, and myopic choroidal neovascularization. Surgical interventions like pars plana vitrectomy and anti-VEGF therapies are used to treat complications, but visual outcomes can still be poor due to underlying retinal degeneration and abnormalities caused by high myopia. Early diagnosis and treatment is important to prevent vision loss from myopic maculopathy.
CYCLODIODE LASER FOR GLAUCOMA -AJAY DUDANIAjayDudani1
This document discusses transscleral contact diode laser cyclophotocoagulation (CPC) for treating refractory glaucomas. It provides details on the procedure, including using a diode laser probe placed against the sclera to deliver shots around the limbus. The author notes CPC can lower IOP within 6 weeks by damaging the ciliary pigment epithelium and stroma. Their study of 150 patients found 30-50% IOP reduction using this technique, with repeat laser needed in 40% at 3-6 months. Complications can include hyphema, hypotony, uveitis and rare cases of phthisis, but the procedure provides IOP control in over 90% and a lower
This document provides an overview of different types of corneal dystrophies, including their classification, clinical features, histopathology, and management. It discusses epithelial and subepithelial dystrophies, corneal dystrophies of Bowman's layer, stromal corneal dystrophies, and Descemet membrane and endothelial dystrophies. The key points are that corneal dystrophies are inherited, bilateral, and slowly progressive disorders that begin early in life and are characterized by corneal opacification without relationship to environmental factors. Diagnosis involves classification based on the anatomical layer affected and treatment typically involves managing symptoms although surgery may be needed if vision is impaired.
1. Endophthalmitis is an intraocular inflammation that predominantly affects the inner spaces of the eye.
2. It can be classified as infectious (exogenous or endogenous) or non-infectious. The most common type is exogenous endophthalmitis, which accounts for over 85% of cases.
3. Treatment depends on the type and severity of endophthalmitis. For acute postoperative endophthalmitis with vision of light perception or worse, immediate pars plana vitrectomy and intravitreal antibiotics is recommended. For vision of hand motions or better, a tap and inject of intravitreal antibiotics is recommended initially.
This document discusses automated perimetry, which is an important diagnostic test for mapping the visual field in an automated way to diagnose and monitor diseases like glaucoma. It describes the basics of perimetry testing including light intensity measurements, stimulus size, threshold testing, and different testing methods. It then explains how to interpret perimetry results by analyzing zones like reliability indices, total and pattern deviation plots, global indices, and other metrics to determine if defects are present and compatible with a condition like glaucoma.
Congenital nasolacrimal duct obstruction is a common cause of tearing in infants, where the nasolacrimal duct fails to fully canalize after birth. Signs include tearing and eye discharge, especially with colds. Treatment first involves massage and antibiotics, with probing of the duct under anesthesia if not resolved by 12-18 months. Probing has a high success rate when done early. Surgery like dacryocystorhinostomy may be needed if probing fails or for membranous obstructions. The procedure involves creating a passage from the lacrimal sac to the nasal cavity with good long-term success rates over 90% typically.
Gonioscopy is an examination of the anterior chamber angle using a gonioscopy lens and slit lamp microscope. It allows visualization of key angle structures including the trabecular meshwork, Schwalbe's line, scleral spur, and ciliary body band. The examination is used to diagnose glaucoma and angle closure risk. There are two main techniques - direct gonioscopy using a contact lens and indirect gonioscopy using a single or multiple mirror lens. Angle structures may be difficult to see, requiring manipulations like indentation and corneal wedge to improve visualization. Gonioscopy is essential for glaucoma evaluation and management.
This document discusses astigmatism, presbyopia, and aphakia. It defines these conditions and describes their causes, symptoms, diagnosis, and treatment options. For astigmatism, it covers the different types including regular, irregular, and mixed astigmatism. It discusses optical correction using lenses, refractive surgery options like LASIK, and intraocular lenses. For presbyopia, it defines the condition, describes the age-related decline in accommodation, symptoms, and treatments like multifocal lenses, contact lenses, and refractive surgery options.
Minimally Invasive Glaucoma Surgery (MIGS)Meironi Waimir
Minimally invasive glaucoma surgery (MIGS) is a group of procedures that minimizes the invasive rate of glaucoma with five characteristics: ab interno microincision, minimal trauma, more effective, high safety profile, and quick recovery.
MIGS is a surgery that uses an incision in a clear cornea and is indicated in patients with mild to moderate open angle glaucoma.
The technique of MIGS is based on several mechanisms, namely trabecular meshwork bypass stents including iStent, trabectome, and Hydrus microstent; Suprachoroidal implant using Cypass microstent; And subconjungtiva filtration using XEN gel stent.
MIGS technology has potential advantages in glaucoma management by reducing the burden of treatment, improving patients quality of life, and cutting or delaying more invasive surgeries.
Nasolacrimal duct obstruction can be congenital or acquired. It results in a blockage of the lacrimal drainage system which transports tears from the eye to the nose. The document describes the anatomy of the lacrimal drainage system and classifications of NLDO. Causes include infections, inflammation, tumors, trauma, and mechanical obstruction. Diagnosis involves history, examination, Jones dye testing, and imaging. Treatment depends on the type and includes massage, probing, dacryocystorhinostomy, and occasionally intubation or stenting. Surgical treatment aims to re-establish drainage from the lacrimal sac into the nose.
This document discusses potential complications of trabeculectomy, both intraoperative and postoperative. Intraoperative complications include buttonholing of the conjunctiva, scleral flap tears, lens injury, vitreous prolapse, hyphema, and suprachoroidal hemorrhage. Postoperative complications can be early such as hypotony, elevated intraocular pressure, choroidal effusions or late such as thin blebs, infections, and cataracts. Management strategies are provided for addressing complications depending on the specific issue.
This document summarizes kinetic versus static perimetry and automated perimetry. Kinetic perimetry involves moving a stimulus across the visual field to plot isopters, while static perimetry measures sensitivity at fixed retinal locations. Automated perimetry uses static techniques with computer control, allowing tests like Humphrey and Octopus to efficiently and objectively measure thresholds across the visual field.
Dr. Reshma's presentation covered the clinical evaluation of squint, including taking a thorough patient history, assessing visual acuity and refraction under cycloplegia, and evaluating motor and sensory status. Key parts of the evaluation include measuring any ocular deviation using cover tests, evaluating versions and vergences, and testing binocular vision functions like suppression and stereopsis. A thorough exam is important for establishing the cause of strabismus and diagnosing amblyopia or other issues.
The document discusses plastic surgery, its benefits and risks. It interviews a plastic surgeon, Dr. Ali Manafi, about his experience and views on plastic surgery. He notes that the most important factors for a successful procedure are choosing the right patient and surgical technique. While cosmetic surgery can improve self-esteem if done correctly, psychological disorders often underlie the desire for it and surgery will not satisfy patients with body dysmorphic disorder. Rhinoplasty is currently the most common cosmetic procedure performed.
This document discusses the dangers and ineffectiveness of angioplasty compared to lifestyle changes and bypass surgery for treating coronary obstruction. It states that angioplasty is risky, provides only a temporary solution, and has high costs both financially and in terms of health risks. By contrast, lifestyle changes can prevent or reverse obstruction in many cases. For those who need intervention, bypass surgery provides a complete and long-term solution at a lower cost than repeated angioplasty procedures. The document concludes that lifestyle changes should be the first approach, with bypass surgery as the preferred intervention over angioplasty.
This document discusses target intraocular pressure (IOP) for treating glaucoma. It defines target IOP as the upper limit of IOP that prevents further glaucoma damage. Establishing an individualized target IOP is important to slow retinal ganglion cell loss and glaucoma progression over a patient's lifetime with minimal effects on quality of life. The target IOP should be based on factors like the amount of existing eye damage, maximum past IOP levels, life expectancy, and risk factors. The target is dynamic and must be reevaluated periodically, lowering it if damage progresses or raising it if side effects occur from low IOP. Clinical studies show that greater IOP reductions correlate with less glaucoma progression
Circumscribed choroidal hemangioma is a benign vascular tumor that occurs as an orange-red mass in the posterior pole of the eye. It most commonly causes decreased vision through serous retinal detachment. Diagnosis can be challenging as it is often initially misdiagnosed as choroidal melanoma or metastasis. Imaging such as ultrasound, fluorescein angiography, and MRI help differentiate it from other lesions. Asymptomatic lesions may be observed, while visually threatening lesions require treatment such as photodynamic therapy, laser photocoagulation, or radiotherapy. Factors like delayed treatment and poor initial vision predict a worse visual outcome.
Traumatic cataracts are caused by blunt or penetrating ocular trauma and can form immediately or years later. The majority require surgery. Factors like mechanism of injury, lens morphology, integrity of structures like the capsule and zonules, and presence of other ocular injuries must be considered for surgical planning. Cataract extraction techniques may include phacoemulsification, extracapsular extraction, or lensectomy depending on the case. Postoperative care involves managing complications and determining appropriate intraocular lens placement. Prognosis depends on initial findings and injuries per the Ocular Trauma Score.
Optical coherence tomography (OCT) is useful for imaging both the anterior and posterior segments in glaucoma. Posterior segment OCT allows quantification of retinal nerve fiber layer thickness, optic nerve head parameters, and ganglion cell layer thickness. Changes in these measurements over time can help detect glaucomatous progression. Anterior segment OCT visualizes angle anatomy and structures after glaucoma surgery. OCT provides objective data but results must be interpreted carefully while considering limitations such as variability between devices and lack of representation in normative databases.
Optic atrophy refers to changes in the optic nerve resulting from axonal degeneration between the retina and lateral geniculate body, causing visual disturbance and changes in the optic nerve head appearance. It can be classified as primary, secondary, or consecutive. Primary optic atrophy occurs without prior nerve swelling and may result from lesions along the visual pathway. Secondary optic atrophy is preceded by long-term nerve swelling and includes causes like chronic papilledema. Consecutive optic atrophy is caused by diseases of the inner retina or its blood supply. Neuroretinitis refers to optic neuritis with retinal inflammation, most commonly caused by cat scratch fever, and presents with papillitis, macular edema, and sometimes a macular
This document discusses minimally invasive glaucoma surgery (MIGS) procedures. It defines MIGS as glaucoma surgery that is ab interno, uses a small incision, spares the conjunctiva, causes minimal trauma and tissue disruption, has a high safety profile, allows for rapid visual recovery, and can be combined with cataract surgery. It then describes various MIGS procedures including trabecular micro-bypass stents, gonioscopy assisted transluminal trabeculotomy, excimer laser trabeculotomy, the iStent, and suprachoroidal shunts. It provides details on the mechanisms, surgical techniques, indications, and complications of these different MIGS procedures.
1. The document presents a case of a 20-year-old male with involuntary eye movements since birth, blurry distant vision for 5 years, and recurrent eye pain and discomfort for 7 years. Examination found nystagmus and a diagnosis of infantile nystagmus syndrome was made.
2. The discussion section defines nystagmus and its mechanisms, describes features like waveforms and territories, and covers types of nystagmus including congenital sensory deficit nystagmus, congenital motor nystagmus, and spasmus nutans.
3. Congenital nystagmus is often idiopathic but can be hereditary, and genetic factors like mutations
Myopic Maculopathy refers to pathologies that can occur in the macula as a result of high myopia and pathological myopia. Some key pathologies discussed in the document include posterior staphyloma, lacquer cracks, macular hemorrhage, myopic foveoschisis, myopic macular hole, and myopic choroidal neovascularization. Surgical interventions like pars plana vitrectomy and anti-VEGF therapies are used to treat complications, but visual outcomes can still be poor due to underlying retinal degeneration and abnormalities caused by high myopia. Early diagnosis and treatment is important to prevent vision loss from myopic maculopathy.
CYCLODIODE LASER FOR GLAUCOMA -AJAY DUDANIAjayDudani1
This document discusses transscleral contact diode laser cyclophotocoagulation (CPC) for treating refractory glaucomas. It provides details on the procedure, including using a diode laser probe placed against the sclera to deliver shots around the limbus. The author notes CPC can lower IOP within 6 weeks by damaging the ciliary pigment epithelium and stroma. Their study of 150 patients found 30-50% IOP reduction using this technique, with repeat laser needed in 40% at 3-6 months. Complications can include hyphema, hypotony, uveitis and rare cases of phthisis, but the procedure provides IOP control in over 90% and a lower
This document provides an overview of different types of corneal dystrophies, including their classification, clinical features, histopathology, and management. It discusses epithelial and subepithelial dystrophies, corneal dystrophies of Bowman's layer, stromal corneal dystrophies, and Descemet membrane and endothelial dystrophies. The key points are that corneal dystrophies are inherited, bilateral, and slowly progressive disorders that begin early in life and are characterized by corneal opacification without relationship to environmental factors. Diagnosis involves classification based on the anatomical layer affected and treatment typically involves managing symptoms although surgery may be needed if vision is impaired.
1. Endophthalmitis is an intraocular inflammation that predominantly affects the inner spaces of the eye.
2. It can be classified as infectious (exogenous or endogenous) or non-infectious. The most common type is exogenous endophthalmitis, which accounts for over 85% of cases.
3. Treatment depends on the type and severity of endophthalmitis. For acute postoperative endophthalmitis with vision of light perception or worse, immediate pars plana vitrectomy and intravitreal antibiotics is recommended. For vision of hand motions or better, a tap and inject of intravitreal antibiotics is recommended initially.
This document discusses automated perimetry, which is an important diagnostic test for mapping the visual field in an automated way to diagnose and monitor diseases like glaucoma. It describes the basics of perimetry testing including light intensity measurements, stimulus size, threshold testing, and different testing methods. It then explains how to interpret perimetry results by analyzing zones like reliability indices, total and pattern deviation plots, global indices, and other metrics to determine if defects are present and compatible with a condition like glaucoma.
Congenital nasolacrimal duct obstruction is a common cause of tearing in infants, where the nasolacrimal duct fails to fully canalize after birth. Signs include tearing and eye discharge, especially with colds. Treatment first involves massage and antibiotics, with probing of the duct under anesthesia if not resolved by 12-18 months. Probing has a high success rate when done early. Surgery like dacryocystorhinostomy may be needed if probing fails or for membranous obstructions. The procedure involves creating a passage from the lacrimal sac to the nasal cavity with good long-term success rates over 90% typically.
Gonioscopy is an examination of the anterior chamber angle using a gonioscopy lens and slit lamp microscope. It allows visualization of key angle structures including the trabecular meshwork, Schwalbe's line, scleral spur, and ciliary body band. The examination is used to diagnose glaucoma and angle closure risk. There are two main techniques - direct gonioscopy using a contact lens and indirect gonioscopy using a single or multiple mirror lens. Angle structures may be difficult to see, requiring manipulations like indentation and corneal wedge to improve visualization. Gonioscopy is essential for glaucoma evaluation and management.
This document discusses astigmatism, presbyopia, and aphakia. It defines these conditions and describes their causes, symptoms, diagnosis, and treatment options. For astigmatism, it covers the different types including regular, irregular, and mixed astigmatism. It discusses optical correction using lenses, refractive surgery options like LASIK, and intraocular lenses. For presbyopia, it defines the condition, describes the age-related decline in accommodation, symptoms, and treatments like multifocal lenses, contact lenses, and refractive surgery options.
Minimally Invasive Glaucoma Surgery (MIGS)Meironi Waimir
Minimally invasive glaucoma surgery (MIGS) is a group of procedures that minimizes the invasive rate of glaucoma with five characteristics: ab interno microincision, minimal trauma, more effective, high safety profile, and quick recovery.
MIGS is a surgery that uses an incision in a clear cornea and is indicated in patients with mild to moderate open angle glaucoma.
The technique of MIGS is based on several mechanisms, namely trabecular meshwork bypass stents including iStent, trabectome, and Hydrus microstent; Suprachoroidal implant using Cypass microstent; And subconjungtiva filtration using XEN gel stent.
MIGS technology has potential advantages in glaucoma management by reducing the burden of treatment, improving patients quality of life, and cutting or delaying more invasive surgeries.
Nasolacrimal duct obstruction can be congenital or acquired. It results in a blockage of the lacrimal drainage system which transports tears from the eye to the nose. The document describes the anatomy of the lacrimal drainage system and classifications of NLDO. Causes include infections, inflammation, tumors, trauma, and mechanical obstruction. Diagnosis involves history, examination, Jones dye testing, and imaging. Treatment depends on the type and includes massage, probing, dacryocystorhinostomy, and occasionally intubation or stenting. Surgical treatment aims to re-establish drainage from the lacrimal sac into the nose.
This document discusses potential complications of trabeculectomy, both intraoperative and postoperative. Intraoperative complications include buttonholing of the conjunctiva, scleral flap tears, lens injury, vitreous prolapse, hyphema, and suprachoroidal hemorrhage. Postoperative complications can be early such as hypotony, elevated intraocular pressure, choroidal effusions or late such as thin blebs, infections, and cataracts. Management strategies are provided for addressing complications depending on the specific issue.
This document summarizes kinetic versus static perimetry and automated perimetry. Kinetic perimetry involves moving a stimulus across the visual field to plot isopters, while static perimetry measures sensitivity at fixed retinal locations. Automated perimetry uses static techniques with computer control, allowing tests like Humphrey and Octopus to efficiently and objectively measure thresholds across the visual field.
Dr. Reshma's presentation covered the clinical evaluation of squint, including taking a thorough patient history, assessing visual acuity and refraction under cycloplegia, and evaluating motor and sensory status. Key parts of the evaluation include measuring any ocular deviation using cover tests, evaluating versions and vergences, and testing binocular vision functions like suppression and stereopsis. A thorough exam is important for establishing the cause of strabismus and diagnosing amblyopia or other issues.
The document discusses plastic surgery, its benefits and risks. It interviews a plastic surgeon, Dr. Ali Manafi, about his experience and views on plastic surgery. He notes that the most important factors for a successful procedure are choosing the right patient and surgical technique. While cosmetic surgery can improve self-esteem if done correctly, psychological disorders often underlie the desire for it and surgery will not satisfy patients with body dysmorphic disorder. Rhinoplasty is currently the most common cosmetic procedure performed.
This document discusses the dangers and ineffectiveness of angioplasty compared to lifestyle changes and bypass surgery for treating coronary obstruction. It states that angioplasty is risky, provides only a temporary solution, and has high costs both financially and in terms of health risks. By contrast, lifestyle changes can prevent or reverse obstruction in many cases. For those who need intervention, bypass surgery provides a complete and long-term solution at a lower cost than repeated angioplasty procedures. The document concludes that lifestyle changes should be the first approach, with bypass surgery as the preferred intervention over angioplasty.
This document discusses the dangers and ineffectiveness of angioplasty compared to lifestyle changes and bypass surgery for treating coronary obstruction. It states that angioplasty is risky, provides only a temporary solution, and has high costs both financially and in terms of health risks. By contrast, lifestyle changes can prevent or reverse obstruction in many cases. For those who need intervention, bypass surgery provides a complete and long-term solution at a lower cost than repeated angioplasty procedures. The document concludes that lifestyle changes should be the first approach, with bypass surgery as the preferred intervention over angioplasty.
This document discusses the dangers and ineffectiveness of angioplasty compared to lifestyle changes and bypass surgery for treating coronary obstruction. It states that angioplasty is risky, provides only a temporary solution, and has high costs both financially and in terms of health risks. By contrast, lifestyle changes can prevent or reverse obstruction in many cases. For those who need intervention, bypass surgery provides a complete and long-term solution at a lower cost than repeated angioplasty procedures. The document concludes that lifestyle changes should be the first approach, with bypass surgery as the preferred intervention over angioplasty.
Dr Himadri Sikhor Das pursued radiology after becoming fascinated by the vast knowledge of anatomy and pathophysiology demonstrated by radiology residents while he was a surgery resident. He now owns his own successful radiology practice. Some of the benefits of owning his own practice include freedom and flexibility to set his own protocols. Some challenges in setting up a radiology lab included securing funding for equipment, finding an appropriate location, and obtaining necessary government clearances and approvals. He deals with challenges by fully understanding the problem and then working to find solutions without shortcuts. His advice for radiology students is to work hard to build a strong foundation in disease anatomy and pathology.
Presentazione a cura della Dottoressa Rosella Pasqualoni e del dottor Gregorio Reda - "TIROIDE 2018 Nuovi approcci diagnostici e terapeutici" - Roma 24/11/2018
Role of multi-layer foam dressings with Safetac in the prevention of pressure...GNEAUPP.
This document reviews evidence from clinical and laboratory studies on the use of multi-layer foam dressings with Safetac in preventing pressure ulcers. It finds that:
1) Randomized controlled trials and other clinical studies show these dressings can reduce pressure ulcers on areas like the sacrum and heels when used prophylactically.
2) Laboratory studies indicate these dressings can mediate the effects of pressure, friction, and shear on the skin through their multilayer structure and composition.
3) Taken together, the evidence suggests these dressings may be beneficial for clinicians, healthcare providers, and patients when used as part of standard prevention strategies.
This study examined factors that contribute to interruptions in radiation treatment for cancer patients. Over a 15-month period, 1220 patients received radiation therapy, with 100 (7%) experiencing interruptions. Through counseling, 25 patients agreed to resume treatment. The most common causes of interruptions included financial issues (15%), toxicity (20%), social issues (12%), and death (15%). The study found that providing counseling at multiple timepoints during treatment can help address issues and decrease interruptions. However, larger and more rigorous studies are still needed to better understand barriers and develop solutions.
Short spreecast pp for january 27, 2014Tom Colquitt
This document discusses the importance of proper breathing and airway health. It makes three key points:
1. Dentists' primary responsibility is to examine patients' airways and help patients become nasal breathers. A patient's teeth are secondary to airway health.
2. Treating dental issues without addressing airway problems is ineffective. Modern sleep medicine only addresses end-stage airway disease rather than preventing issues.
3. Public awareness of the link between breathing, airway health, and overall wellness is needed to drive changes in how the medical and dental fields address these issues.
This document discusses best practices for patient care in radiology departments. It emphasizes that patients should be treated with safety, quality care, comfort and minimal radiation exposure. It also stresses the importance of clear communication between radiology staff and patients to avoid errors. The document provides recommendations for optimizing various aspects of the patient experience, including minimizing wait times, increasing communication, and making the environment more welcoming. It suggests radiologists take a more active role in interacting with patients. Finally, it discusses various protocols to ensure patient privacy, safety and informed consent are maintained during examinations.
Wavelength February 2012 Volume 16 No. 1Jerry Duncan
1) Elekta recently acquired Nucletron, the world leader in brachytherapy, consolidating its position as a complete provider of radiation oncology.
2) Brachytherapy involves placing a radiation source inside or next to the tumor, allowing high doses to be delivered over a short period while minimizing side effects.
3) Brachytherapy is often used in combination with other therapies like surgery and external beam radiation for cancers of the prostate, breast, gynecological organs, and is being studied for use in additional cancers and treatment combinations.
The document discusses abdominal MRI on the new MAGNETOM Prisma 3T scanner. It notes the advantages of 3T MRI include higher signal-to-noise ratio and contrast-to-noise ratio, allowing for improved spatial resolution and lesion detection. However, challenges at 3T include increased magnetic field inhomogeneities and susceptibility artifacts. The MAGNETOM Prisma addresses these challenges through technical advances, such as improved B0 and B1 field homogeneity which provide better image quality for liver imaging compared to standard 3T scanners. The article demonstrates examples of reduced distortion and improved diffusion-weighted imaging of the liver on MAGNETOM Prisma.
This study evaluated the lateral tarsal strip technique for correcting lower eyelid ectropion in 30 patients (41 eyelids). Patients were divided into groups based on the type of ectropion: involutional, paralytic, or cicatricial. Most patients presented with tearing. The technique successfully corrected ectropion in 35 eyelids, while 6 required additional procedures. The lateral tarsal strip proved effective for correcting ectropion, especially when lateral canthal tendon laxity is present.
We know that mesothelioma patients would rather stay local when receiving treatment,rnso we will review options for private medical centers, surgical consultants, clinical trials,rnand match you up with friendly, local physicians wherever we can.
We know that mesothelioma patients would rather stay local when receiving treatment,rnso we will review options for private medical centers, surgical consultants, clinical trials,rnand match you up with friendly, local physicians wherever we can.
We know that mesothelioma patients would rather stay local when receiving treatment,rnso we will review options for private medical centers, surgical consultants, clinical trials,rnand match you up with friendly, local physicians wherever we can.
We know that mesothelioma patients would rather stay local when receiving treatment,rnso we will review options for private medical centers, surgical consultants, clinical trials,rnand match you up with friendly, local physicians wherever we can.
Doctors work multiple strategies for Minimally Invasive Surgery. The surgery causes less harm to the body than as compared to Open Surgery. Thus, benefiting in lesser pain and fewer complications. The surgical process involves one or more small incisions, little tubes, and tiny cameras and surgical instruments.
PET CT imaging provides higher sensitivity, specificity and accuracy than conventional imaging for detecting cancer in children. However, there are concerns about radiation exposure from PET CT scans potentially increasing cancer risk. The benefits of PET CT for pediatric oncology patients must be balanced against this radiation risk. PET CT may be appropriate for staging, restaging, treatment response monitoring and residual mass assessment for certain pediatric malignancies when it could improve diagnosis and guide further life-saving treatment.
”DVT Prevention What Works BestSHINE BELL, .docxodiliagilby
This document summarizes a presentation on deep vein thrombosis (DVT) prevention strategies. It begins with an objective to determine the most effective DVT prophylaxis and presents a PICO question comparing pharmacological, mechanical and combination interventions. A literature review found mixed results, with some studies favoring pharmacological prophylaxis alone or in combination with mechanical. The presentation evaluates pros and cons of different prophylaxis types and recommends increased nursing education and a standardized DVT assessment tool. It concludes that further research is needed to determine the best prophylaxis approach in acute care settings.
Similar to Interventional Glaucoma: SLT and MIGS (20)
“Adjusting the Faucet or Opening the Drain – Currently Available Methods to Treat the Plumbing Problem of Open Angle Glaucoma”
A San Gabriel Valley Optometric Society (SGVOS) Continuing Education Dinner Event – 2 hours CE | Featured Speaker: Dr. David Richardson, MD | April 12, 2017
Learn more about Dr. David Richardson: http://David-Richardson-MD.com
Femtosecond Laser-Assisted Cataract Surgery (FLACS) - David Richardson, MDDr David Richardson
The document discusses the benefits of exercise for mental health. Regular physical activity can help reduce anxiety and depression and improve mood and cognitive function. Exercise stimulates the production of endorphins in the brain which elevate mood and reduce stress levels.
So You've Got a Cataract - Health Talk at Crowell Public LibraryDr David Richardson
Dr. David Richardson talks about cataracts, cataract Surgery, types of intraocular lenses, and laser cataract surgery or laser-assisted cataract surgery.
TALK Details
WHEN: Friday, January 8, 2016 from 11:00 AM to 12:00 PM
WHERE: Crowell Public Library - 1890 Huntington Drive, San Marino, CA 91108, United States
ABOUT Dr. Richardson
Dr. Richardson is an Adjunct Assistant Professor Of Clinical Ophthalmology at the Keck School of Medicine of University of Southern California. He is currently the Medical Director and Chief Surgeon of San Marino Eye and serves as Vice Chief of Staff at San Gabriel Valley Medical Center. He has authored a patient-centered book on Cataract, “So, You’ve Got A Cataract?” and has written many articles about glaucoma and cataract surgery on his blogs, New-Glaucoma-Treatments.com and About-Eyes.com, respectively.
For full transcription, visit About-Eyes.com: http://about-eyes.com/so-youve-got-a-cataract-health-talk-at-crowell-public-library
What's New In Glaucoma Surgery [OD CE 2 credit hours] - PPT Slides and VideosDr David Richardson
What's New In Glaucoma Surgery Presentation. A Continuing Education course for Optometrists presented by Patient-Focused Ophthalmologist, Dr. David Richardson.
At the end of the presentation audience participants became familiar with the main benefits and risks of currently available glaucoma treatments as well as had awareness of the most promising potential future surgical glaucoma treatments.
This OD CE Course was held at Green Street Tavern, Pasadena, CA last May 20, 2015.
=========================
[Glaucoma Surgeon, California] Dr. David Richardson is a board certified Ophthalmologist and Eye Surgeon in California specializing in the treatment of Cataract and Glaucoma. He is the Medical Director of San Marino Eye (Vision Center), located in San Marino, California. He’s the former Chief of Surgery and now Vice Chief of Staff at San Gabriel Valley Medical Center. Dr. Richardson has performed thousands of advanced cataract and Canaloplasty glaucoma procedures with excellent results.
More information about Dr. Richardson: http://David-Richardson-MD.com
New Glaucoma Treatments is a GLAUCOMA HealthHub maintained by David Richardson, M.D. It’s primary purpose is to provide valuable information to glaucoma patients and their caregivers worldwide about the latest developments and treatments for glaucoma, while providing answers to commonly asked questions about glaucoma, care and treatment options.
More information about new glaucoma treatments here: http://new-glaucoma-treatments.com
Canaloplasty New Glaucoma Treatment – HealthTalk at San Gabriel Valley Medica...Dr David Richardson
This document discusses canaloplasty, a new minimally invasive glaucoma treatment. It provides background on glaucoma, risk factors for the disease, and current treatment options like laser surgeries, trabeculectomy, and drainage devices. The document then focuses on canaloplasty, describing it as a non-penetrating procedure that uses a flexible microcatheter to pass through the eye's drainage canal 360 degrees. It notes the benefits of canaloplasty include lower intraocular pressure and fewer medication requirements compared to traditional surgeries, with a safer profile and no complications. A quote from the inventor of canaloplasty praises it as the closest procedure to having no complications.
The introduction of canaloplasty into the glaucoma surgical armamentarium was motivated by the desire of clinicians to enhance the quality of patients’ glaucoma care. Patients’ long-term adherence to topical glaucoma medical therapy is well known to be relatively poor. Laser therapy offers a safe alternative to medical therapy but often still requires the addition of topical medication. Traditionally, glaucoma filtration surgery has been reserved for more advanced, uncontrolled glaucoma for obvious reasons. Despite its definite role in glaucoma care, patients undergoing standard trabeculectomy are at significant risk for the development of postoperative infection, cataract, hypotony, bleb dysesthesia, astigmatism, and decreased visual acuity. These potential complications have driven surgeons to pursue surgical alternatives. Canaloplasty is a well-established procedure that has, for the past 3 years, demonstrated impressive efficacy and safety in peer-reviewed prospective studies. Despite growing evidence of its value and increasing performance of the procedure by ophthalmologists all over the world, misconceptions regarding its long-term efficacy as well as challenges in its adoption, surgical
technique, and patient selection persist. Several experienced and leading surgeons share their experiences and pearls for optimizing success with canaloplasty.
— Steven D. Vold, MD
Glaucoma is a lifestyle disease. Its treatment via traditional surgery (ie. trabeculectomy) or via glaucoma medications, negatively impacts the lifestyle of patients. In this presentation, Dr. David Richardson presents the new, non-invasive glaucoma treatment, Canaloplasty. Canaloplasty is a lifestyle surgery for Glaucoma.
Travel Clinic Cardiff: Health Advice for International TravelersNX Healthcare
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Know the difference between Endodontics and Orthodontics.Gokuldas Hospital
Your smile is beautiful.
Let’s be honest. Maintaining that beautiful smile is not an easy task. It is more than brushing and flossing. Sometimes, you might encounter dental issues that need special dental care. These issues can range anywhere from misalignment of the jaw to pain in the root of teeth.
How to Control Your Asthma Tips by gokuldas hospital.Gokuldas Hospital
Respiratory issues like asthma are the most sensitive issue that is affecting millions worldwide. It hampers the daily activities leaving the body tired and breathless.
The key to a good grip on asthma is proper knowledge and management strategies. Understanding the patient-specific symptoms and carving out an effective treatment likewise is the best way to keep asthma under control.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
2. 2 SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY | AUGUST 2018
IQBAL “IKE” K. AHMED, MD, FRCSC, MODERATOR
n Professor of Ophthalmology, University of Utah, and Assistant Professor and Director of the
Glaucoma and Advanced Anterior Surgical Fellowship, University of Toronto, Canada
n ike.ahmed@utoronto.ca
n Financial disclosure: Consultant (Ellex)
MARK J. GALLARDO, MD
n In Private Practice at El Paso Eye Surgeons in El Paso, Texas
n gallardomark@hotmail.com
n Financial disclosure: Consultant (Ellex), Clinical Investigator for the ABiC Procedure
MAHMOUD A. KHAIMI, MD
n Clinical Professor at the Dean McGee Eye Institute, University of Oklahoma, Oklahoma City
n mahmoud-khaimi@dmei.org
n Financial disclosure: Consultant (Ellex), Clinical Investigator for the ABiC Procedure
NATHAN M. RADCLIFFE, MD
n Clinical Assistant Professor in the Department of Ophthalmology at New York Eye and Ear
Infirmary, New York City
n drradcliffe@gmail.com
n Financial disclosure: Consultant (Ellex)
DAVID D. RICHARDSON, MD
n Adjunct Assistant Professor of Clinical Ophthalmology, Keck School of Medicine, University of
Southern California, Los Angeles
n In Private Practice at San Marino Eye in San Marino, California
n david.richardson@sanmarinoeye.co
n Financial disclosure: Consultant (Ellex)
INDER PAUL SINGH, MD
n Glaucoma Specialist, President of The Eye Centers of Racine and Kenosha, Racine, Wisconsin
n ipsingh@amazingeye.com
n Financial disclosure: Speaker (Ellex)
To watch videos of this roundtable, go to eyetube.net/collection/ellex/jrfal/
PARTICIPANTS
3. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
AUGUST 2018 | SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY 3
At ASCRS 2018 in Washington, DC, a group of surgeons experienced in interventional glaucoma therapies sat down to
discuss the roles of selective laser trabeculoplasty (SLT) and microinvasive glaucoma surgery (MIGS) for treatment of open-
angle glaucoma (OAG).
The term interventional glaucoma refers to more than simply technology. It is a mindset that the available technologies
bring to us as surgeons and clinicians. Instead of being passive and watchful, waiting for our patients to progress, interventional
glaucoma allows us to be actively involved in their care by providing interventional therapies that change the course of the
disease. I am very excited about interventional glaucoma and how it shapes the future of glaucoma care.
In this roundtable, we will discuss a number of technologies used in the interventional glaucoma model. First, we want to hear
about SLT and its relevance in glaucoma therapy today, including the interplay of SLT and MIGS options. We also will talk about
our experiences with ab interno canaloplasty (ABiC) performed with the iTrack surgical system (Ellex), its role in rejuvenating the
natural outflow system, and its place among MIGS procedures. —Iqbal “Ike” K. Ahmed, MD, FRCSC, Moderator
SLT AND MIGS: AN INTERVENTIONAL APPROACH
s
Dr. Ahmed: I want to keep it pretty open to start, just
talking about your current treatment paradigms for
OAG. Tell me your thoughts.
Inder Paul Singh, MD: I think it depends on your target
pressure, of course, but maintaining the patient’s quality of
life is always key for me. How can I get pressure down, main-
tain the pressure long term, and maintain a high quality of
life? To meet those goals, I try to minimize patients’ reliance
on drops, thereby avoiding all of the various compliance
issues we face. I tend to use SLT as a first line, if possible, and
now also offer MIGS procedures earlier than I would offer
traditional glaucoma surgeries, in an effort to minimize the
impact of compliance in this long-term disease. Drops are
always there as an adjunct as needed.
Mark J. Gallardo, MD: I agree—minimizing medication reli-
ance is critical. In fact, when I encounter a glaucoma patient
with mild to moderate disease with a visually significant cata-
ract, I use that as an opportunity to manage both the patient’s
cataract and glaucoma. Unlike in the past, when I would rarely
couple a cataract surgery with our more invasive filtration
procedures in such patients, I now almost always automatically
couple the patient’s cataract surgery with a glaucoma sur-
gery—a MIGS procedure. I do this because of the proven safety
and efficacy in both IOP and medication reduction, and mini-
mal additional recovery compared to cataract surgery alone.
Dr. Ahmed: We can draw from a few categories of glau-
coma therapy. We have medications, interventional therapies
like SLT and MIGS, and more traditional surgeries such as tra-
beculectomy and tube shunt. Tell me about how you use SLT
and MIGS in conjunction with each other in your practice.
Mahmoud A. Khaimi, MD: My treatment paradigm is to
go to SLT as primary therapy, and then use a MIGS procedure
like ABiC with the iTrack microcatheter after that. If the dis-
ease progresses, my next steps would be perhaps SLT again,
and then maybe some other MIGS, pushing back filtering and
tube surgeries to later stages. In this paradigm, medication
has actually fallen to kind of an adjunct in between those
treatment stages. I think that’s the way we’re heading.
David D. Richardson, MD: I agree with that. I think that,
at least here in the United States, it has always been an issue
with medical/legal acceptability to go straight to a proce-
dure instead of starting with medication. The safety profile
of SLT is so great, I would argue that it’s actually a safer first
option than many of the medications. We talk about, for
example, the beta-blockers as being a potential problem
because they can have an impact on older patients. I actu-
ally had a younger, athletic patient end up in the emergency
room because of his reaction to beta-blockers. So medica-
tions not only carry issues of adherence and cost, even with
generics, but also health risks. I’ve never had a patient go to
the emergency room after SLT. Never.
INTERVENTIONAL GLAUCOMA:
SLT AND MIGS
A roundtable discussion of nondestructive interventional treatments for open-angle glaucoma.
4. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
4 SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY | AUGUST 2018
Dr. Singh: You’re right. And I’d add that there is the
medications’ toxicity to consider as well. Also, most of our
medications also divert fluid away from the natural outflow.
The ability of SLT to maintain the flow through the trabecu-
lar meshwork (TM) as well as the canal and distal chan-
nels means we can maximize the flow through the natural
outflow systems as early as possible. That not only lowers
pressure but also has the potential to prime the area for use
of MIGS at a later time. Using SLT and MIGS earlier is very
important to increase compliance, minimize toxicity, and
improve the flow for long-term effect.
Dr. Ahmed: It sounds like most of you are using SLT early
in the treatment paradigm, and in your experiences, patients
are receiving that option quite well. Other than thinking
about it as a primary therapeutic response, how do you feel
about using SLT as an indicator of response to MIGS?
Dr. Singh: This is something that my colleagues and I have
studied. Recently, we conducted a retrospective analysis
of our first iStent Trabecular Micro-Bypass Stent (Glaukos)
cases with at least a 1-year follow-up. We found that patients
had done well overall. When we analyzed the subset of
patients who had previous SLT, we found those with histori-
cally a good response to SLT had better IOP reduction and
were on less postoperative medications than the patients
who historically did not have a response to SLT.
These outcomes made us reexamine SLT as a possible
diagnostic tool and provided our first inkling that we needed
to examine the location of future MIGS treatment. SLT
works at the TM, right? So, if it works well, we can conclude
that the flow is probably good in the canal and distal chan-
nels. If it does not work well, then there might be some
downstream resistance.
Now a positive SLT outcome leads me to think a trabecu-
lar bypass might be sufficient as well as ABiC with iTrack,
while a poor effect of SLT leads me to conclude that the
patient might have better results if we focused not just on
the TM, but rather on the entire outflow pathway, includ-
ing the distal channels, which would lead me to rely on a
procedure like ABiC with iTrack. We are still studying the
outcomes to determine if this is an accurate predictor.
Dr. Khaimi: Whether SLT works or it doesn’t, I still do
ABiC with iTrack afterward because I think it’s a little bit
more powerful than other MIGS options and it comprehen-
sively treats everything. So, perhaps we weren’t able to open
up the TM very well with SLT, but with ABiC viscodilating
so much of the canal, I think it opens up the TM well. To
me, SLT is a good indicator of whether ABiC will be effec-
tive afterward, but if SLT doesn’t work, that doesn’t keep me
from doing ABiC.
Dr. Singh: I agree with you. I think that’s one of the most
important points. I probably wouldn’t do a TM bypass-only
device after unsuccessful SLT. That’s where I think ABiC with
iTrack can really help out in those patients.
Nathan M. Radcliffe, MD: We’re moving toward stand-
alone MIGS procedures, and SLT is sort of the grandfather of
standalone glaucoma interventions. A patient who did well
with that SLT intervention is sort of psychologically primed
to think, “I trusted Dr. Radcliffe. He told me there would be a
The safety profile of SLT is so great,
I would argue that it’s actually a safer first option
than many of the medications.
—David D. Richardson, MD
The ability of SLT to maintain the flow through the
trabecular meshwork as well as the canal and distal
channels means we can maximize the flow through
the natural outflow systems as early as possible. That
not only lowers pressure but also has the potential to
prime the area for use of MIGS at a later time.
—Inder Paul Singh, MD
David D. Richardson, MD
5. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
AUGUST 2018 | SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY 5
laser, that I would recover very nicely, and that it could work.
It worked. That was 4 years ago. Now things have changed
with my glaucoma, and he’s recommending ABiC. I’ll do it.”
Our patients are buying into this paradigm. As we gain expe-
rience and confidence with SLT, we’ll feel more confident in
offering these safe, standalone MIGS procedures. The end
result is that we’re changing the overall paradigm to what
Dr. Ahmed has called interventional glaucoma.
MISCONCEPTIONS ABOUT SLT
s
Dr. Ahmed: SLT has been around for some time, but
I think there are still some misconceptions floating
around about the procedure. Could you talk about
some of the misconceptions you encounter with SLT
and how you clarify them for people?
Dr. Radcliffe: Yes, there are many misconceptions (see Six
Misconceptions About SLT sidebar). At a conference like this
one, I’m overwhelmed with a flood of questions from our
colleagues and friends. “Can you do SLT on someone who’s
never been on medication?” Yes. “And insurance will pay
for that?” Yes. “But doesn’t it cost the insurance company
more?” No. It saves the insurance company money over
medication. “But not if they’re on generics.” Yes, even if the
patient is taking generics—and particularly if the patient is
taking price-gouging generics, which we see more and more.
As a bonus, while medications like dorzolamide (Trusopt,
Santen) can be taken away, SLT treatment cannot.
Dr. Singh: One misconception I hear from some doctors is
that they don’t believe that SLT even works. In a study that
compared SLT to a prostaglandin analog, researchers found
similar efficacy without the toxicity, costs, and compliance
challenges.1
Years ago, a lot of us used to use trabeculoplasty,
especially argon laser trabeculoplasty (ALT), when glaucoma
was more advanced. After trying three or four medications,
we thought, “OK, fine, I’ll do trabeculoplasty.” But in contrast,
SLT works much better earlier in the disease progression
because we have a healthier outflow system. Perhaps that
contributes to this big misconception.
Dr. Ahmed: What’s your experience with repeatability of SLT?
Dr. Khaimi: If a patient has good results for a year, I’ll
usually try to repeat SLT. It’s not destructive. Maybe that’s
another misconception we should mention as well. Some
folks might confuse ALT and SLT, as Dr. Singh mentioned.
I don’t think that we can do ALT anymore because we’re
doing MIGS as a first-line surgical treatment now. There’s a
big theme of rejuvenation in glaucoma now. SLT achieves
that, and then we’re rejuvenating the TM a little bit more
with ABiC with iTrack. So, unlike ALT, SLT’s nondestructive
nature does not preclude future MIGS treatment options.
Dr. Radcliffe: I would just add that just because we can
repeat SLT, that doesn’t mean that we will have to do so.
Again, this gets back to some people thinking that SLT
doesn’t work, or patients believing, “It’s only going to work
for a year or two, so what’s the point?” I’ve seen it work for
9 years. It seems to patients like a cure at that point, and if I
have to repeat SLT every 9 years, I think I’m doing great.
Dr. Khaimi: Are those the patients you treat early on?
Dr. Radcliffe: Yes. A patient might be on a prostaglan-
din analog for 6 weeks, does not like the side effects, so we
decide to go for SLT. Patients like this have had known glau-
coma for only a period of weeks to months. Anyone who
seizes those cases early and treats with SLT will never ques-
tion whether it works. People who use SLT too late, maybe
to try to get out of surgery, aren’t positioned to get the best
I don’t think that we can do ALT anymore
because we’re doing MIGS as a first-line surgical
treatment now. There’s a big theme of rejuvenation
in glaucoma now. SLT achieves that, and then
we’re rejuvenating the TM a little bit more with
ABiC with iTrack. So, unlike ALT, SLT’s
nondestructive nature does not preclude
future MIGS treatment options.
—Mahmoud A. Khaimi, MD
Mahmoud A. Khaimi, MD
6. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
6 SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY | AUGUST 2018
results. Those are the ones who question the efficacy. But if
they use SLT early, they will see the results.
Dr. Gallardo: You have to question why SLT doesn’t work
in those patients who have been on medications for years.
One reason that we don’t really discuss: we’ve known for
10 or 15 years that the preservative in the drops actually
damages the TM. We’re using drops to help a patient’s pres-
sure, but at the same time, we’re damaging the system that
naturally relieves the pressure. If we can minimize or even
eliminate the patient’s need for medications, we will actually
help reduce the deleterious effects that the benzalkonium
chloride is causing to the conventional outflow system.
Can you imagine if there were a cholesterol medication
that helped oxygenate the heart, but at the same time
closed off the coronary arteries? No one would ever use
it, but we do something similar to that every day with eye
drops. We prescribe medications that we know, over time,
damage the eyes’ primary outflow system. We also know
that chronic medication use will adversely affect the viability
of filtration procedures by inducing cytokine and interleukin
infiltration into the conjunctiva, but we prescribe them rou-
tinely. I’ve always wanted to minimize the need for medica-
tions as much as I can.
MIGS IN DAILY PRACTICE
s
Dr. Ahmed: Let’s switch gears to MIGS. MIGS
procedures have exploded on the scene. There are
lots of options out there. What MIGS are you using?
Where do they fit into your approach?
Dr. Gallardo: I’m a proponent of the idea that every
device and procedure has its place. In any one routine
OR day, I perform several MIGS procedures. I evaluate each
patient and try to find the procedure that I feel best fits the
patient’s pathology by assessing the drainage angle via goni-
oscopy, stage of glaucoma, and looking at the patient’s pres-
sure and number of medications. As a result, I use various
MIGS devices and procedures for patients whose glaucoma
is anywhere from mild to severe, and I try to utilize MIGS
prior to doing any filtering procedure.
Dr. Singh: It’s a similar principle to selecting premium
lenses. Which patient needs which MIGS? We never had that
ability in the past, but now we can select the right MIGS for
each situation. We are now able to tailor our treatment for
each patient. It’s great to have options.
Dr. Ahmed: What percentage of your practice is combina-
tion cataract-MIGS surgery, versus standalone MIGS? How
do you use MIGS for those situations?
Dr. Khaimi: I’m doing more combined surgery, about
60/40 or 70/30. I want to take advantage of the opportunity
for patients with vision impaired by cataracts, who are on
multiple drops, to be treated with a MIGS procedure that
brings down their ocular pressure. I think that’s a great time
to capture them. Of course, it also dramatically improves
their quality of life.
Dr. Singh: For me, the numbers have changed. A few
years ago, I did about 90% cataract-MIGS procedures and
10% standalone MIGS. With all of the new MIGS products
available to us, including ABiC with iTrack and others, the
current ability to do standalone procedures has allowed
me to treat more patients earlier, especially pseudophakic
patients who are not tolerating medications. Nowadays,
even if the fields and nerves are stable, but the patients
can’t afford the medications, can’t remember to take them,
or are just not happy, I offer a MIGS procedure. Now I can
tell those patients, “I’d like to discuss a procedure that is
safe and efficient overall and could get rid of some of your
drops.” That threshold has changed, and now I’m probably
We’ve known for 10 or 15 years that the preservative
in the drops actually damages the TM. We’re using
drops to help a patient’s pressure, but at the same
time, we’re damaging the system that naturally
relieves the pressure.
—Mark J. Gallardo, MD
Mark J. Gallardo, MD
7. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
AUGUST 2018 | SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY 7
SIX MISCONCEPTIONS ABOUT SLT
By Nathan M. Radcliffe, MD
Colleagues often ask me questions about selective laser trabeculo-
plasty (SLT), and I hear a lot of myths. I’m happy to debunk them and
share the facts about SLT.
MYTH 1: SLT IS NOT AN EFFECTIVE FIRST-LINE THERAPY
“Does SLT really work?” It’s a common question. The quick answer is
“Yes,” but I would add that SLT is both effective and a wise choice as
a first-line therapy for the following reasons:
• SLT works as well or better than topical
medications.1
One study of SLT as primary
therapy showed that mean IOP
reduction was 7.3 to 8.3 mm Hg
at 1 year.2
• In another study that compared
SLT to prostaglandin as pri-
mary therapy, IOP reduction was
similar at 9 to 12-month follow-
up (6.3 mm Hg for SLT, versus
7.0 mm Hg for medication).3
• SLT opens up the trabecular
meshwork, helping restore nat-
ural flow through the canal and
distal channels, which should
help sustain outflow and make future treatments easier.
• SLT alleviates the problems of compliance, ocular surface toxicity,
meibomian gland dysfunction, and high costs related to taking one
or more medications long term.
MYTH 2: SLT CANNOT BE REPEATED (OR SLT MUST BE REPEATED)
Some surgeons fear that they only have one chance to do SLT, and
others who believe in repeating it think that this must happen every
2 years on the clock. However, the truth is that SLT is repeatable but
does not always require repeating. IOP reduction from the second
SLT is typically comparable to the first, and the results last longer.4
Some patients, more than 10 years out, have never needed the sec-
ond treatment. If I perform SLT and fall short of the goal I know that
repeat therapy may achieve it. I find that patients understand the idea
of repeat SLT treatment, and because the experience is comfortable
for them, they do not hesitate about having a second SLT.
MYTH 3: SLT IS NOT EFFECTIVE OVER THE LONG TERM
SLT causes remodeling and healing of the trabecular meshwork. By
utilizing SLT as a primary therapy or treatment early in the disease pro-
cess, we increase the likelihood of long-term effect. In a long-term study
that included 88 eyes with SLT, IOP was lowered -6.7 ± 7.1 at 3 years,
-7.0 ± 7.7 at 4 years and -7.4 ± 7.3 at 5 years, with some patients requir-
ing additional interventions during the follow-up period.5
MYTH 4: SLT CANNOT BE PERFORMED AFTER ALT OR LPI
In my experience, the outcomes for SLT after argon laser trabeculo-
plasty (ALT) are the same as we see for patients who have never had
laser treatment. SLT is an excellent choice, in fact, because it does not
cause thermal damage or scarring to the trabecular meshwork.
In patients with narrow angles who have had previous laser
peripheral iridotomy (LPI), I consider the angle to be “primed” by
the trabecular acquisition. SLT works just as well here as in primary
open-angle glaucoma.6 If the angle is freshly opened, then we
know where the disease is located. I treat them with SLT, get them
off drops, and they end up with outcomes similar to patients
without narrow angles.
MYTH 5: SLT ONLY WORKS IN PIGMENTED ANGLES
My colleague, Paul Harasymowycz, MD,
reviewed 70 of his patients and
analyzed what baseline factors cor-
related with good IOP lowering.7 He
found that having a higher baseline
IOP was related to getting a better
pressure reduction, and that patients
on a prostaglandin analog didn’t get
quite as much lowering. However, age,
angle pigmentation, phakic status,
gender, or diagnosis did not impact efficacy,
so these patients may all be treated without
concern of baseline factors throwing off laser success.
MYTH 6: SLT IS NOT RELEVANT IN THE ERA OF MIGS
Eyes with a high baseline pressure tend to respond to many
procedures. A factor called corneal hysteresis predicts who will
have good IOP reduction from SLT.8 Successful SLT tells us that
resistance to outflow was located in the trabecular meshwork,
while SLT that does not meet goals tells us that a microinvasive
glaucoma surgery (MIGS) procedure or other intervention should
target another mechanism.
1. Kadasi LM, Wagdi S, Miller KV. Selective laser trabeculoplasty as primary treatment for open-angle glaucoma. RIMed
J(2013). 2016;99(6):22-25.
2. Realini T. Selective laser trabeculoplasty for the management of open-angle glaucoma in St. Lucia. JAMAOphthalmol.
2013;131(3):321-327.
3. Katz LJ, Steinmann WC, Kabir A, et al. Selective laser trabeculoplasty versus medical therapy as initial treatment of
glaucoma: a prospective, randomized trial. JGlaucoma. 2012;21(7):460-468.
4. Avery N, Ang GS, Nicholas S, Wells A. Repeatability of primary selective laser trabeculoplasty in patients with primary
open-angle glaucoma. IntOphthalmol. 2013;33(5):501-506.
5. Bovell AM, Damji KF, Hodge WG, et al. Long term effects on the lowering of intraocular pressure: selective laser or
argon laser trabeculoplasty? CanJOphthalmol.2011;46(5):408-413.
6. Ali Aljasim L, Owaidhah O, Edward DP. Selective laser trabeculoplasty in primary angle-closure glaucoma after laser
peripheral iridotomy: a case-control study. JGlaucoma. 2016;25(3):e253-258.
7. Bruen R, Lesk MR, Harasymowycz P. Baseline factors predictive of SLT response: a prospective study. JOphthalmol.
2012;2012:642869.
8. Hirneiß C, Sekura K, Brandlhuber U, et al. Corneal biomechanics predict the outcome of selective laser trabeculoplasty
in medically uncontrolled glaucoma. GraefesArchClinExpOphthalmol. 2013;251(10):2383-2388.
8. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
8 SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY | AUGUST 2018
about 60/40 with more stand-
alone MIGS than before.
ABiC IN THE SPOTLIGHT
s
Dr. Ahmed: Let’s focus on
one of the MIGS: ABiC with
iTrack. We’ve all used this
system, and I think there
is increasing interest in
the procedure. Could a
few of you describe how
ABiC works, in terms of its
mechanism of action and
how it lowers pressure?
Dr. Richardson: I describe
ABiC to my patients as essentially
angioplasty for the eye. We take
a drainage system that has been
stopped up and we expand it,
rejuvenating the natural outflow. Patients get that, because
they all understand what angioplasty is.
One of the things that I like about ABiC with iTrack is
how we approach it. I take a step-wise approach with MIGS.
First I want to use SLT to get the TM working better. If the
improvement is not enough, then I want to make sure that
the outflow system is truly open by using ABiC with iTrack.
The next step, in my opinion, is placing a stent, so we’re
creating a communication pathway. So that’s the step-wise
approach that I take, and patients understand that. You’ve
got an obstruction, you’ve got a drainage system behind
that, and then sometimes you have to open it up. It’s nice,
because it’s a very simple, straightforward, easily understood
discussion to have.
Dr. Khaimi: That’s truly the epitome of interventional
glaucoma therapy. The mechanism with ABiC is viscodilation
of Schlemm canal, which might be collapsed or have herni-
ated TM in it. We’re also creating intratrabecular fractures
and beams that allow aqueous to flow through diseased TM
and out through the conventional outflow pathway.
There are a lot of pretty revolutionary MIGS options, but I
like to start off with ABiC first. There is a misconception that
it only works on the canal distally. I think that ABiC compre-
hensively treats all outflow channels, which is why it is my first
go-to MIGS procedure. I don’t have the diagnostic capability
to know where the obstruction is located or what level of
resistance exists, so I like to start off with a MIGS that address-
es everything. The other advantage is that ABiC doesn’t burn
any bridges. I can do any other procedure afterwards because
it isn’t destructive, and I don’t have to worry about a device.
Dr. Richardson: We were talking earlier about SLT being
a diagnostic tool. ABiC with iTrack has the same potential.
If it doesn’t work, then there’s no point in going in later and
putting in a stent or a scaffold. A failed ABiC is telling you
this system is not capable of being reopened. Fortunately,
that’s quite rare, but if we’re looking at a step-wise approach,
I would not place a stent in a patient who does not respond
to ABiC. Instead, I would look at a suprachoroidal shunt or
another approach.
Dr. Radcliffe: Dr. Khaimi, could you explain the phrase
“trabecular herniation?” I just learned about this.
Dr. Khaimi: When pressures increase, we see trabecular
meshwork herniating into Schlemm canal. Haiyan Gong,
MD, PhD, in Boston has assembled a lot of beautiful pathol-
ogy slides showing POAG compared to normal eyes. POAG
eyes tend to have a lot more herniations, especially complete
herniations.2
I tell my patients, “Your canal looks like this
when it’s working normally. But if it has become clogged or
collapsed, we need to balloon it open.” We need to alleviate
the trabecular herniation.
Left to right: Inder Paul Singh, MD; Nathan M. Radcliffe, MD; David D. Richardson, MD; Mark J. Gallardo, MD; Mahmoud A.
Khaimi, MD; and Iqbal “Ike” K. Ahmed, MD, FRCSC.
I describe ABiC to my patients as essentially
angioplasty for the eye. We take a drainage system
that has been stopped up and we expand it,
rejuvenating the natural outflow. Patients get that,
because they all understand what angioplasty is.
—David D. Richardson, MD
9. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
AUGUST 2018 | SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY 9
Dr. Gallardo: To add to Dr. Khaimi’s comments, Dr. Gong
found that in postmortem POAG eyes fixed at 0 mm Hg,
95% of collector channels were obstructed by these TM
herniations, while in non-POAG or normal eyes, only 15% of
collector channels were obstructed despite being fixated at
10 mm Hg.1
The iTrack catheter itself lyses these herniations
within the canal, in addition to viscodilating the distal system.
Robert Stegmann, MD, also showed that while viscodilat-
ing Schlemm canal using the iTrack catheter, microperfora-
tions within the inner wall of Schlemm canal are created.3
The microperforations help counter the reduction in the
inter- and intracellular micropore population exhibited in
glaucoma patients. Given the endothelial cells of Schlemm
canal are connected by tight-junctions, it is thought that
these micropores help facilitate aqueous outflow through
the inner wall and into Schlemm canal.
Dr. Ahmed: We know the nondestructive nature of ABiC
with iTrack. We’ve heard about the multiple mechanisms of
action, plus its proximal system and distal system. We’ve been
using it. What about our colleagues? What are the barriers to
adoption? Are they technical or knowledge related? What bar-
riers have you seen, and how do you approach them?
Dr. Gallardo: The most challenging portion of the proce-
dure is the initial intubation of the canal. Once the catheter
is in the canal, it’s very easy to thread the iTrack throughout
the canal’s entirety.
Surgeons who are not MIGS trained at this point face the
same barriers as any new surgeon to the angle. They need to
learn to obtain a clear view of the nasal angle with a direct sur-
gical gonioprism as well as to manipulate surgical tools within
the angle. However, if a surgeon is MIGS trained, I think the
barriers to ABiC are minimal. They will have a limited learning
curve because they’re already in the angle, and it won’t be dif-
ficult for them to achieve success with this procedure.
Dr. Radcliffe: I was performing MIGS already, but I was
probably the last of this group to adopt ABiC, and I think
you’re right. Maybe it seemed a little bit intimidating, but
actually not only was it fun to adopt, but it was enjoyable
as well. I felt the thrill of actually doing surgery on the canal
rather than just putting things in it in one simple shot.
What impressed me was the level of confidence I had dur-
ing the procedure. I knew I was achieving the anatomical
goal for the canal. I think surgeons commonly aren’t quite
sure that they’re where they want to be in the canal, and this
solves that problem 100 percent. Surprisingly for me, I think I
felt more confident that I had achieved my surgical goal after
my first ABiC procedure than I ever felt with a TM proce-
dure. It was just so clear as the anatomy literally lit up, with
the iTrack going around the circle, that I was certain it was
right. It was fun, too. I said, “Why did I wait so long?”
My barriers to adoption were, first, some misconcep-
tions. For example, I thought that I had to buy a big device
that illuminates the iTrack microcatheter. I didn’t realize
that it was easily obtainable with the first case without a
capital investment. The other barrier is that it can be very
difficult to change practice patterns. We have to find out
who our rep is, make a phone call, and talk to a colleague
who’s been doing it. If I operated in the same OR as an
iTrack user, I would have adopted it a long time ago, but I
had to start without any exposure. Once I got the ball roll-
ing, it was easy. If there’s a lesson learned for me, it’s that
there’s no need to wait.
Dr. Ahmed: How does ABiC with iTrack compare to the
other MIGS out there, and where does it fit?
Dr. Khaimi: A lot of the other MIGS are stents that bypass
the obstruction. For example, iStent bypasses a diseased
TM. Cypass Micro-Stent (Alcon) is a suprachoroidal device.
With ABiC, no device is implanted in the eye. We use the
iTrack catheter to go around the canal, and as Dr. Radcliffe
described, we can see exactly where we’re going. There’s no
I think that ABiC comprehensively treats outflow
locations, which is why it is my first go-to MIGS
procedure. I don’t have the diagnostic capability
to know where the obstruction is located or what
level of resistance exists, so I like to start off with a
MIGS that addresses everything.
—Mahmoud A. Khaimi, MD
Dr. Gong found that in postmortem POAG eyes
fixed at 0 mm Hg, 95% of collector channels were
obstructed by these TM herniations, while in
non-POAG or normal eyes, only 15% of collector
channels were obstructed despite being fixated
at 10 mm Hg. The iTrack catheter itself lyses
these herniations within the canal, in addition to
viscodilating the distal system.
—Mark J. Gallardo, MD
10. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
10 SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY | AUGUST 2018
guessing game. That’s a big thing for me. I’m a belt-and-sus-
penders kind of guy, so if I think that the disease process is
somewhere along the line from the TM to the distal region,
it’s nice to be certain that I’m in the area I want to treat.
Dr. Richardson: In a comparison of trabeculectomy to
all of the available alternative procedures, the only two that
came close were glaucoma drainage devices and ab externo
canaloplasty.4 The work that Dr. Gallardo and Dr. Khaimi
have done has indicated that ABiC with iTrack produces
results that are quite close to what we can expect from ab
externo canaloplasty.5 So, while we don’t have a direct com-
parison among all of the players, the results certainly sug-
gest that ABiC with iTrack may be a bit more effective than
other MIGS options that we have, without a destructive ab
externo procedure.
Dr. Ahmed: What does your the typical ABiC with iTrack
patient look like?
Dr. Singh: I think the beauty of ABiC with iTrack is that a
large population of patients can benefit from the procedure.
It’s not just for a patient who is pseudophakic at the time of
cataract surgery. Another nice feature is that it can be used
for mild to moderate glaucoma as well as advanced disease.
I’ve performed it on postoperative trabeculectomy and tube
patients, in cases where there was good visualization and
access to the TM. I find that the selection of patients is very
broad, so when I want to manage the natural outflow system
for any patient, this is a very universal choice.
In Dr. Khaimi and Dr. Gallardo’s respective data, ABiC
worked very well used both as a standalone and in combi-
nation with cataract surgery, as well as in different types of
patient populations.4
For those who had starting pressures
Inder Paul Singh, MD
While various MIGS devices may work on
specific sections of the outflow system,
ABiC’s multiple mechanisms let us hedge our
bets and, in my opinion, have a better chance of
getting that reduction of pressure in the right type
of patient population.
—Inder Paul Singh, MD
What percentage of the MIGS you perform is shunt/
canal-based procedures versus supraciliary/
subconjunctival procedures?
n Shunt/Canal Based
n Supraciliary/Subconjunctival
DR. RADCLIFFE
DR. SINGH
DR. RICHARDSON
DR. KHAIMI
70%
70%
30%
30%
90%
10%
90%
10%
DR. GALLARDO
65%
35%
Figure 1. Shunt/canal-based versus supraciliary/subconjunctival procedures.
DR. AHMED
50%
50%
11. INTERVENTIONAL GLAUCOMA: SLT AND MIGS
AUGUST 2018 | SUPPLEMENT T0 CATARACT REFRACTIVE SURGERY TODAY 11
that were high or in the middle to upper teens, you saw a
significant reduction that was maintained. For those who
had lower, more controlled IOPs, ABiC with iTrack kept the
IOPs low but reduced the drop burden significantly. That
responder rate is what excites me. We don’t know where the
resistance to outflow is preoperatively. Is it the TM, Schlemm
canal, or distal? While various MIGS procedures may work
on specific sections of the outflow system, ABiC’s multiple
mechanisms let us hedge our bets and, in my opinion, have
a better chance of getting that reduction of pressure in the
right type of patient population. As long as I have a good
angle and can see it very well, I think the patient is a very
good candidate for ABiC.
HOW HAS MIGS CHANGED YOUR PRACTICE?
s
Dr. Ahmed: What percentage of the MIGS you
perform is shunt/canal-based versus supraciliary or
subconjunctival (Figure 1)?
Dr. Gallardo: I would say about 60 to 70% of my MIGS
procedures are performed on the conventional outflow
system. For me, it’s the safest system to work with because
there’s virtually no risk for hypotony owing to the back wall
of the episcleral venous system, and it has proven efficacy
at reducing pressure and medication burden. After that, I
prefer to use the suprachoroidal space, which has also been
shown to be quite effective but has a tad bit higher risk for
adverse events. Typically, my subconjunctival procedures are
for patients who need a filter.
Dr. Richardson: I do about 90%-plus conventional outflow.
Dr. Singh: I’d say I perform about 70% natural outflow
MIGS and 30% other devices. I still try and maximize natural
outflow if possible as a first choice for many patients.
Dr. Radcliffe: I’ve got a severe glaucoma practice. If I set
aside my tube shunts and just look at MIGS procedures,
then I do at least 60% conventional outflow—maybe as high
as 75%. The rest are split between supraciliary and subcon-
junctival MIGS. The fact that ABiC has insurance coverage
available to my standalone patients and to a full spectrum of
health insurance companies helps me provide this option to
more people.
Dr. Khaimi: I’m a canal-based guy, so I’ve always focused
on conventional outflow. I’ve dabbled with a lot of other
things, too, but when I go subconjunctival, it’s usually to
push that trabeculectomy farther downstream.
CONCLUSION
s
Dr. Ahmed: You guys have shared a lot of experience
today. I thought we’d finish off the roundtable
by talking about what excites you in the future
of glaucoma therapy, whether it’s something
about diagnostics, your practice, MIGS, or other
treatments. What are you excited to see in the next
5 years?
Dr. Khaimi: Well, I wish we had MIGS a long time ago.
I’m at a tertiary center, so I see many patients with severe
glaucoma. We talk a lot about improving their quality of life
with MIGS, but those options also dramatically improve the
doctor’s quality of life. There’s a lot of less patient chair time.
Patients are happy and doing well. It’s an extremely excit-
ing time. We can now rejuvenate and restore the outflow
system—it doesn’t get better than that. We were taught to
bypass the natural outflow when we first started out, and
now we can restore it.
Dr. Richardson: I love the idea that we’re getting to the
point where we can talk about doing multiple less risky
procedures together, or in short step-wise approach, to
potentially achieve the same outcome as trabeculectomy
or glaucoma drainage devices with far less risk. If we can get
to the point where we do multiple MIGS procedures at the
same time for moderate and severe glaucoma patients, then
we’ll achieve the desired effect. For both patients and, as you
mentioned, for the doctors as well, the low-risk outcomes
are going to be wonderful.
Dr. Ahmed: Dr. Radcliffe, you always have something up
your sleeve.
Dr. Radcliffe: Of course! Well, I look at myself 10 years ago
using SLT only for severe glaucoma, and now it’s my primary
therapy of choice. I’m hoping that in the next 10 years, or
maybe even sooner, I can make that same kind of transition
to bring standalone, canal-based procedures into my mind-
set and into my practice. In order to make this reflexive and
be more proactive, we all have to change our attitudes and
our thoughts. We need to get consensus. It takes time to
I would say about 60 to 70% of my MIGS procedures
are performed on the conventional outflow system.
For me, it’s the safest system to work with because
there’s virtually no risk for hypotony owing to
the back wall of the episcleral venous system, and
it has proven efficacy at reducing pressure and
medication burden.
—Mark J. Gallardo, MD